



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Measures

<i>(Dollars in Millions Except Per Share Data)</i>	Third Quarter		% Incr. / (Decr.)	Nine Months YTD		% Incr. / (Decr.)
	2011	2010		2011	2010	
Earnings before provision for taxes on income - as reported	\$ 4,111	4,219	(2.6) %	\$ 12,043	14,719	(18.2) %
Restructuring - Cordis	-	-		676	-	
Net Litigation Settlements Loss (Gain) & DePuy ASR™ Hip recall costs*	-	-		763	(1,340)	
Currency option adjustment and deal costs related to planned acquisition of Synthes	316	-		214	-	
Earnings before provision for taxes on income - as adjusted	<u>\$ 4,427</u>	<u>4,219</u>	<u>4.9 %</u>	<u>\$ 13,696</u>	<u>13,379</u>	<u>2.4 %</u>
Net Earnings - as reported	\$ 3,202	3,417	(6.3) %	\$ 9,454	11,392	(17.0) %
Restructuring - Cordis	-	-		549	-	
Net Litigation Settlements Loss (Gain) & DePuy ASR™ Hip recall costs*	-	-		596	(977)	
Currency option adjustment and deal costs related to planned acquisition of Synthes	241	-		139	-	
Net Earnings - as adjusted	<u>\$ 3,443</u>	<u>3,417</u>	<u>0.8 %</u>	<u>\$ 10,738</u>	<u>10,415</u>	<u>3.1 %</u>
Diluted Net earnings per share - as reported	\$ 1.15	1.23	(6.5) %	\$ 3.40	4.08	(16.7) %
Restructuring - Cordis	-	-		0.20	-	
Net Litigation Settlements Loss (Gain) & DePuy ASR™ Hip recall costs*	-	-		0.22	(0.35)	
Currency option adjustment and deal costs related to planned acquisition of Synthes	0.09	-		0.05	-	
Diluted Net earnings per share - as adjusted	<u>\$ 1.24</u>	<u>1.23</u>	<u>0.8 %</u>	<u>\$ 3.87</u>	<u>3.73</u>	<u>3.8 %</u>

*DePuy ASR™ Hip recall costs are in 2011 only.

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.